CN1287774C - 用于吸入的组合物 - Google Patents

用于吸入的组合物 Download PDF

Info

Publication number
CN1287774C
CN1287774C CNB038031221A CN03803122A CN1287774C CN 1287774 C CN1287774 C CN 1287774C CN B038031221 A CNB038031221 A CN B038031221A CN 03803122 A CN03803122 A CN 03803122A CN 1287774 C CN1287774 C CN 1287774C
Authority
CN
China
Prior art keywords
pvp
formoterol
peg
pharmaceutical composition
budesonide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038031221A
Other languages
English (en)
Chinese (zh)
Other versions
CN1625392A (zh
Inventor
内伊纳·戈文德
玛丽亚·马洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20286853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1287774(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1625392A publication Critical patent/CN1625392A/zh
Application granted granted Critical
Publication of CN1287774C publication Critical patent/CN1287774C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Networks Using Active Elements (AREA)
  • Pyrane Compounds (AREA)
CNB038031221A 2002-02-01 2003-01-29 用于吸入的组合物 Expired - Lifetime CN1287774C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0200312A SE0200312D0 (sv) 2002-02-01 2002-02-01 Novel composition
SE02003127 2002-02-01
PCT/SE2003/000156 WO2003063842A1 (en) 2002-02-01 2003-01-29 Composition for inhalation

Publications (2)

Publication Number Publication Date
CN1625392A CN1625392A (zh) 2005-06-08
CN1287774C true CN1287774C (zh) 2006-12-06

Family

ID=20286853

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038031221A Expired - Lifetime CN1287774C (zh) 2002-02-01 2003-01-29 用于吸入的组合物

Country Status (27)

Country Link
US (8) US7759328B2 (enExample)
EP (2) EP1474117B1 (enExample)
JP (2) JP2005521663A (enExample)
KR (2) KR20090125857A (enExample)
CN (1) CN1287774C (enExample)
AT (2) ATE463241T1 (enExample)
AU (1) AU2003206289B2 (enExample)
BR (1) BR0307193A (enExample)
CA (1) CA2474479C (enExample)
CO (1) CO5611098A2 (enExample)
CY (2) CY1109030T1 (enExample)
DE (2) DE60332067D1 (enExample)
DK (2) DK2036549T3 (enExample)
ES (2) ES2342509T3 (enExample)
IL (1) IL163160A (enExample)
IS (2) IS7360A (enExample)
MX (1) MXPA04007295A (enExample)
NO (1) NO337006B1 (enExample)
NZ (1) NZ534452A (enExample)
PL (1) PL211836B1 (enExample)
PT (2) PT1474117E (enExample)
RU (1) RU2301673C2 (enExample)
SE (1) SE0200312D0 (enExample)
SI (2) SI2036549T1 (enExample)
UA (1) UA79445C2 (enExample)
WO (1) WO2003063842A1 (enExample)
ZA (1) ZA200406086B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
SI1845994T1 (sl) * 2005-02-11 2009-06-30 Argenta Discovery Ltd Kombinacija metilksantinskih spojin in steroidov za zdrvljenje kroničnih respiratornih bolezni
US9084799B2 (en) 2005-02-11 2015-07-21 Pulmagen Therapeutics (Synergy) Limited Inhaled combination therapy
DE102006053374A1 (de) * 2006-02-09 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
US20130160761A1 (en) * 2008-11-04 2013-06-27 Cipla Limited Pharmaceutical Aerosol Composition
NZ574666A (en) 2009-02-05 2009-04-30 Nexus6 Ltd A medicament inhaler holder that uses optical means to count and display the number of doses used
WO2010112358A2 (de) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh Verfahren zur beschichtung einer oberfläche eines bauteils
WO2010133294A2 (de) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalationseinrichtung und zerstäuber
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EA026241B1 (ru) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Распылитель
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
WO2012007729A2 (en) * 2010-07-16 2012-01-19 Cipla Limited Pharmaceutical compositions
EP2600829B1 (en) * 2010-08-03 2017-06-14 Chiesi Farmaceutici S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
US8574630B2 (en) * 2010-09-22 2013-11-05 Map Pharmaceuticals, Inc. Corticosteroid particles and method of production
US20120204871A1 (en) 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US9241904B1 (en) 2011-08-19 2016-01-26 Intech Biopharm Ltd. Method for preparing metered dose sprayed inhaler for treating respiratory disease
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
EP3139984B1 (en) 2014-05-07 2021-04-28 Boehringer Ingelheim International GmbH Nebulizer
AU2015257878B2 (en) 2014-05-07 2019-08-08 Boehringer Ingelheim International Gmbh Container, nebulizer and use
EA033013B1 (ru) 2014-05-07 2019-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Контейнер, индикаторное устройство и небулайзер
WO2016018892A1 (en) * 2014-07-29 2016-02-04 3M Innovative Properties Company Method of preparing a pharmaceutical composition
BR122020022602B1 (pt) 2015-12-04 2024-03-05 Mexichem Fluor S.A. De C.V. Composição farmacêutica
CN106581010B (zh) * 2016-12-28 2019-03-05 四川普锐特医药科技有限责任公司 一种气溶胶制剂及定量吸入气雾剂
US11344562B2 (en) 2017-08-15 2022-05-31 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
CA3103679A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
JP7402631B2 (ja) 2018-08-27 2023-12-21 帝人株式会社 極細炭素繊維混合物、その製造方法、及び炭素系導電助剤
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
US6123924A (en) * 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
JP3342484B2 (ja) 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
DE19536902A1 (de) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
DK0938467T3 (da) * 1996-11-11 2002-10-07 Sepracor Inc Fremgangsmåde til fremstilling af optisk rene isomerer af formoterol
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0016876D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition

Also Published As

Publication number Publication date
AU2003206289B2 (en) 2007-09-06
EP1474117A1 (en) 2004-11-10
JP5259636B2 (ja) 2013-08-07
UA79445C2 (en) 2007-06-25
CN1625392A (zh) 2005-06-08
ATE423552T1 (de) 2009-03-15
MXPA04007295A (es) 2004-10-29
PL211836B1 (pl) 2012-06-29
US20100275913A1 (en) 2010-11-04
NO337006B1 (no) 2015-12-21
US11311558B2 (en) 2022-04-26
EP2036549A1 (en) 2009-03-18
US20160022703A1 (en) 2016-01-28
RU2004122921A (ru) 2005-06-10
NZ534452A (en) 2006-01-27
PT1474117E (pt) 2009-04-24
JP2005521663A (ja) 2005-07-21
PL372118A1 (en) 2005-07-11
ATE463241T1 (de) 2010-04-15
CY1109030T1 (el) 2014-07-02
US8575137B2 (en) 2013-11-05
NO20043458L (no) 2004-08-19
ZA200406086B (en) 2006-01-25
KR20040081757A (ko) 2004-09-22
US20140286878A1 (en) 2014-09-25
DK2036549T3 (da) 2010-07-12
IL163160A (en) 2013-12-31
DE60332067D1 (de) 2010-05-20
US7759328B2 (en) 2010-07-20
KR100947168B1 (ko) 2010-03-12
KR20090125857A (ko) 2009-12-07
SI1474117T1 (sl) 2009-06-30
CY1110081T1 (el) 2015-01-14
EP1474117B1 (en) 2009-02-25
SE0200312D0 (sv) 2002-02-01
US20190216828A1 (en) 2019-07-18
US20170368078A1 (en) 2017-12-28
WO2003063842A1 (en) 2003-08-07
SI2036549T1 (sl) 2010-07-30
RU2301673C2 (ru) 2007-06-27
US10166247B2 (en) 2019-01-01
ES2342509T3 (es) 2010-07-07
HK1126684A1 (en) 2009-09-11
BR0307193A (pt) 2004-11-03
IS7360A (is) 2004-07-21
DK1474117T3 (da) 2009-05-25
CA2474479C (en) 2011-04-05
ES2321180T3 (es) 2009-06-03
US8143239B2 (en) 2012-03-27
JP2010132695A (ja) 2010-06-17
IS9028A (is) 2013-04-16
WO2003063842A9 (en) 2004-04-22
IS2960B (is) 2017-02-15
US20050089478A1 (en) 2005-04-28
PT2036549E (pt) 2010-06-22
US20210069215A1 (en) 2021-03-11
CO5611098A2 (es) 2006-02-28
US20120216802A1 (en) 2012-08-30
CA2474479A1 (en) 2003-08-07
EP2036549B1 (en) 2010-04-07
DE60326320D1 (de) 2009-04-09

Similar Documents

Publication Publication Date Title
CN1287774C (zh) 用于吸入的组合物
CN105338960B (zh) 用于吸入施用的包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂
AU2003206289A1 (en) Composition for inhalation
CN1805730A (zh) 鼻用药物制剂和使用方法
KR20170093114A (ko) 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물
CN117281796A (zh) 一种治疗奶牛乳房炎的硫酸头孢喹肟缓释制剂及其制备方法
Aghera et al. Formulation and evaluation of sublingual tablets of losartan potassium
WO2000062819A1 (en) Formulations for detecting asthma
Sri Formulation and Evaluation of Nizatidine Microspheres
Rasheed et al. Formulation and in-vitro characterization of erythromycin ocular inserts
CN113940925B (zh) 一种雾化吸入用甲磺酸阿比多尔冻干剂
Siddiqui et al. Formulation of Metformin Sustained Release Tablet Using Natural Polymer
CHATURVEDI et al. Formulation and evaluation solid dispersion based fast dispersible tablets of domperidone.
Ahmed et al. Development and in vitro evaluation of acebrophylline sustained release matrix tablets employing different grade of HPMC and ethyl cellulose
WO2024246776A1 (en) Stable cyclosporine ophthalmic formulation and manufacturing process thereof
Sikilkar et al. FORMULATION AND EVALUATION OF IN-SITU NASAL GEL OF SALBUTAMOL SULPHATE
Cordts Advanced Powder Characterization Techniques for Inhalation Powder Mixtures
HK1126684B (en) Novel composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20061206

CX01 Expiry of patent term